Author:
Ma Brigette,Goh Boon Cher,Tan Eng Huat,Lam Kwok Chi,Soo Ross,Leong Swan Swan,Wang Ling Zhi,Mo Frankie,Chan Anthony T. C.,Zee Benny,Mok Tony
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference16 articles.
1. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983–991
2. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883
3. Chen C, King I, Belcourt M (2002) Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytotoxicity to KB cells. Proc AACR-EORTC conference 38: S26. Abstract 71
4. Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M (2004) A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331–342
5. Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsburger C (2006) Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 81:210–211
Cited by
141 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献